Patents Assigned to Pfizer
  • SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20150336958
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 areas described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: August 7, 2015
    Publication date: November 26, 2015
    Applicant: PFIZER INC.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
    Patent number: 9192612
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: November 24, 2015
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Elizabeth Mary Beck, Jennifer Elizabeth Davoren, Erik Alphie LaChapelle, Brian Thomas O'Neill
  • Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    Patent number: 9193726
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: November 24, 2015
    Assignee: Pfizer Inc.
    Inventors: Martin Youngjin Pettersson, Douglas Scott Johnson, Chakrapani Subramanyam, Christopher John O'Donnell, Christopher William am Ende, Michael Eric Green, Nandini Chaturbhai Patel, Cory Michael Stiff, Tuan Phong Tran, Gregory Wayne Kauffman, Antonia Friederike Stepan, Patrick Robert Verhoest
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20150329555
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: May 18, 2015
    Publication date: November 19, 2015
    Applicant: PFIZER INC.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • N1/N2-lactam acetyl-CoA carboxylase inhibitors
    Patent number: 9181252
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 10, 2015
    Assignee: Pfizer Inc.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith
  • N-link hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 9180123
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: November 10, 2015
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Ye Che, Anthony Marfat, Michael Joesph Melnick, Justin Ian Montgomery, Usa Reilly
  • ANTI-PTK7 ANTIBODY-DRUG CONJUGATES
    Publication number: 20150315293
    Abstract: The present invention provides anti-PTK7 antibody-drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: April 27, 2015
    Publication date: November 5, 2015
    Applicants: STEMCENTRX, INC., PFIZER INC.
    Inventors: Marc Isaac DAMELIN, Puja SAPRA, Alexander John BANKOVICH, Scott J. DYLLA
  • PCSK9 antagonists
    Patent number: 9175093
    Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: November 3, 2015
    Assignees: RINAT NEUROSCIENCE CORP., PFIZER INC.
    Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Xiayang Qiu, Pavel Strop, Yuli Wang
  • Triazine compounds as PI3 kinase and MTOR inhibitors
    Patent number: 9174963
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: November 3, 2015
    Assignee: Pfizer Inc.
    Inventors: Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo Dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Aryl-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20150307494
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: April 23, 2015
    Publication date: October 29, 2015
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, MICHAEL AARON BRODNEY, MICHAEL ERIC GREEN, CHAKRAPANI SUBRAMANYAM
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20150307522
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: April 23, 2015
    Publication date: October 29, 2015
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, SCOT RICHARD MENTE, CHAKRAPANI SUBRAMANYAM
  • Spliceostatin analogs and methods for their preparation
    Patent number: 9169264
    Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 27, 2015
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Frank Erich Koehn, Kenneth John Dirico, Alessandra S. Eustaquio, Michael Eric Green, Haiyin He, Min He, Christopher John O'Donnell, Sujiet Puthenveetil, Anokha Ratnayake, Jesse Alexander Teske, Hui Yu Yang
  • Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
    Patent number: 9163021
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: October 20, 2015
    Assignee: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides
    Publication number: 20150291621
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: April 9, 2015
    Publication date: October 15, 2015
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • N-Aminosulfonyl Benzamides
    Publication number: 20150291514
    Abstract: The present invention relates to sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salts thereof, wherein Z, R1a, R1b, R2, R3, R4 and R5 are as defined in the description, and to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. The compounds of formula (I) are Nav1.7 inhibitors useful in the treatment of a wide range of disorders, particularly pain.
    Type: Application
    Filed: December 21, 2012
    Publication date: October 15, 2015
    Applicant: PFIZER LIMTED
    Inventors: Alan Daniel Brown, Sebastien Rene Gabriel Galan, David Simon Millan, David James Rawson, Robert Ian Storer, Paul Anthony Stupple, NIgel Alan Swain
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20150290165
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 15, 2015
    Applicants: Provectus Pharmaceuticals, Inc., Pfizer, Inc.
    Inventors: Craig J. EAGLE, H. Craig DEES, Eric A. WACHTER, Jamie SINGER
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20150290318
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 15, 2015
    Applicants: Provectus Pharmaceuticals, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors
    Patent number: 9156845
    Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 13, 2015
    Assignee: Pfizer Inc.
    Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Antonia Friederike Stepan, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20150284405
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: April 3, 2015
    Publication date: October 8, 2015
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY
    Publication number: 20150274735
    Abstract: The present invention relates to methods of delaying progression to end stage renal disease (ESRD) in patients comprising administration of 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methyl-pyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide. The present invention also includes administration of pharmaceutical compositions for delaying progression to ESRD. 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methyl-pyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide.
    Type: Application
    Filed: October 9, 2013
    Publication date: October 1, 2015
    Applicant: Pfizer Inc.
    Inventors: Valerie Clerin, Jeremy Gale, Nihad Tamimi